ECSP23086047A - Composición farmacéutica para prevenir o tratar la fibrosis - Google Patents

Composición farmacéutica para prevenir o tratar la fibrosis

Info

Publication number
ECSP23086047A
ECSP23086047A ECSENADI202386047A ECDI202386047A ECSP23086047A EC SP23086047 A ECSP23086047 A EC SP23086047A EC SENADI202386047 A ECSENADI202386047 A EC SENADI202386047A EC DI202386047 A ECDI202386047 A EC DI202386047A EC SP23086047 A ECSP23086047 A EC SP23086047A
Authority
EC
Ecuador
Prior art keywords
prevent
pharmaceutical composition
treat fibrosis
fibrosis
component
Prior art date
Application number
ECSENADI202386047A
Other languages
English (en)
Inventor
Min Young Park
Caroline Hee Lee
Ji Hyeon Kim
Joon Seok Park
Da Jeong Bae
Min Jae Cho
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of ECSP23086047A publication Critical patent/ECSP23086047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica cuyo uso puede resultar de utilidad para prevenir o tratar la fibrosis. De acuerdo con la presente invención, existe la característica de que el efecto preventivo o terapéutico de la fibrosis puede potenciarse utilizando el primer componente y el segundo componente en combinación.
ECSENADI202386047A 2021-05-13 2023-11-14 Composición farmacéutica para prevenir o tratar la fibrosis ECSP23086047A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20210062252 2021-05-13

Publications (1)

Publication Number Publication Date
ECSP23086047A true ECSP23086047A (es) 2023-12-29

Family

ID=84029268

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202386047A ECSP23086047A (es) 2021-05-13 2023-11-14 Composición farmacéutica para prevenir o tratar la fibrosis

Country Status (13)

Country Link
EP (1) EP4338734A1 (es)
JP (1) JP2024516021A (es)
KR (1) KR20220154616A (es)
CN (1) CN117320718A (es)
AR (2) AR125885A1 (es)
AU (1) AU2022274469A1 (es)
BR (1) BR112023023670A2 (es)
CA (1) CA3213455A1 (es)
CO (1) CO2023015482A2 (es)
EC (1) ECSP23086047A (es)
MX (1) MX2023013405A (es)
TW (1) TW202310839A (es)
WO (1) WO2022240036A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5785078B2 (ja) * 2008-08-11 2015-09-24 グラクソスミスクライン エルエルシー 新規アデニン誘導体
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
CN112040950A (zh) * 2018-03-19 2020-12-04 上海偕怡医药科技有限公司 治疗特发性肺纤维化的方法和组合物

Also Published As

Publication number Publication date
CN117320718A (zh) 2023-12-29
AR125885A1 (es) 2023-08-23
BR112023023670A2 (pt) 2024-01-30
EP4338734A1 (en) 2024-03-20
MX2023013405A (es) 2023-11-27
CA3213455A1 (en) 2022-11-17
JP2024516021A (ja) 2024-04-11
TW202310839A (zh) 2023-03-16
AR125886A1 (es) 2023-08-23
CO2023015482A2 (es) 2023-11-30
WO2022240036A1 (ko) 2022-11-17
KR20220154616A (ko) 2022-11-22
AU2022274469A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
CL2023001949A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020)
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
CL2019000228A1 (es) Tratamiento conjunto contra tipos de cáncer hematológico.
MX2022015601A (es) Compuesto para el tratamiento de infecciones coronavirales.
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022000270A2 (es) Inhibidores de enzimas
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
ECSP23086047A (es) Composición farmacéutica para prevenir o tratar la fibrosis
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
UY38982A (es) Composiciones farmacéuticas
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
DOP2023000084A (es) Formulación sólida
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
BR112022003529A2 (pt) Composições e métodos para o tratamento da infecção por influenza a
BR112021021131A2 (pt) Triterpenos pentacíclicos no tratamento de vitiligo
BR112022022327A2 (pt) Moduladores de akt3 e métodos de uso dos mesmos